1
|
Lin DJ, Hardstone R, DiCarlo JA, Mckiernan S, Snider SB, Jacobs H, Erler KS, Rishe K, Boyne P, Goldsmith J, Ranford J, Finklestein SP, Schwamm LH, Hochberg LR, Cramer SC. Distinguishing Distinct Neural Systems for Proximal vs Distal Upper Extremity Motor Control After Acute Stroke. Neurology 2023; 101:e347-e357. [PMID: 37268437 PMCID: PMC10435065 DOI: 10.1212/wnl.0000000000207417] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Accepted: 03/31/2023] [Indexed: 06/04/2023] Open
Abstract
BACKGROUND AND OBJECTIVES The classic and singular pattern of distal greater than proximal upper extremity motor deficits after acute stroke does not account for the distinct structural and functional organization of circuits for proximal and distal motor control in the healthy CNS. We hypothesized that separate proximal and distal upper extremity clinical syndromes after acute stroke could be distinguished and that patterns of neuroanatomical injury leading to these 2 syndromes would reflect their distinct organization in the intact CNS. METHODS Proximal and distal components of motor impairment (upper extremity Fugl-Meyer score) and strength (Shoulder Abduction Finger Extension score) were assessed in consecutively recruited patients within 7 days of acute stroke. Partial correlation analysis was used to assess the relationship between proximal and distal motor scores. Functional outcomes including the Box and Blocks Test (BBT), Barthel Index (BI), and modified Rankin scale (mRS) were examined in relation to proximal vs distal motor patterns of deficit. Voxel-based lesion-symptom mapping was used to identify regions of injury associated with proximal vs distal upper extremity motor deficits. RESULTS A total of 141 consecutive patients (49% female) were assessed 4.0 ± 1.6 (mean ± SD) days after stroke onset. Separate proximal and distal upper extremity motor components were distinguishable after acute stroke (p = 0.002). A pattern of proximal more than distal injury (i.e., relatively preserved distal motor control) was not rare, observed in 23% of acute stroke patients. Patients with relatively preserved distal motor control, even after controlling for total extent of deficit, had better outcomes in the first week and at 90 days poststroke (BBT, ρ = 0.51, p < 0.001; BI, ρ = 0.41, p < 0.001; mRS, ρ = 0.38, p < 0.001). Deficits in proximal motor control were associated with widespread injury to subcortical white and gray matter, while deficits in distal motor control were associated with injury restricted to the posterior aspect of the precentral gyrus, consistent with the organization of proximal vs distal neural circuits in the healthy CNS. DISCUSSION These results highlight that proximal and distal upper extremity motor systems can be selectively injured by acute stroke, with dissociable deficits and functional consequences. Our findings emphasize how disruption of distinct motor systems can contribute to separable components of poststroke upper extremity hemiparesis.
Collapse
Affiliation(s)
- David J Lin
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital.
| | - Richard Hardstone
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Julie A DiCarlo
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Sydney Mckiernan
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Samuel B Snider
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Hannah Jacobs
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Kimberly S Erler
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Kelly Rishe
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Pierce Boyne
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Jeff Goldsmith
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Jessica Ranford
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Seth P Finklestein
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Lee H Schwamm
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Leigh R Hochberg
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| | - Steven C Cramer
- From the Center for Neurotechnology and Neurorecovery (D.J.L., R.H., J.A.D., S.M., H.J., K.S.E., K.R., L.R.H.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School; Division of Neurocritical Care (D.J.L., L.R.H.), Department of Neurology; Stroke Service (D.J.L., S.P.F., L.H.S., L.R.H.), Department of Neurology, Massachusetts General Hospital, Boston; VA RR&D Center for Neurorestoration and Neurotechnology (D.J.L., L.R.H.), Rehabilitation R&D Service, Department of VA Medical Center, Providence, RI; Division of Neurocritical Care (S.B.S.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School; Department of Occupational Therapy (H.J., K.S.E.), MGH Institute of Health Professions, Boston, MA; Department of Rehabilitation (P.B.), Exercise and Nutrition Sciences, University of Cincinnati College of Allied Health Sciences, OH; Department of Biostatistics (J.G.), Columbia University Mailman School of Public Health, New York, NY; Department of Occupational Therapy (J.R.), Massachusetts General Hospital, Boston; School of Engineering (L.R.H.), Brown University, Providence, RI; and Department of Neurology (S.C.C.), University of California, Los Angeles, California Rehabilitation Hospital
| |
Collapse
|
2
|
Cherba M, Brummans BHJM, Hier MP, Giguère L, Chartier G, Jacobs H, Forest VI, Mlynarek A, Sultanem K, Henry M. Framing Concerns about Body Image during Pre- and Post-Surgical Consultations for Head and Neck Cancer: A Qualitative Study of Patient–Physician Interactions. Curr Oncol 2022; 29:3341-3363. [PMID: 35621662 PMCID: PMC9139818 DOI: 10.3390/curroncol29050272] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 04/25/2022] [Accepted: 05/02/2022] [Indexed: 12/04/2022] Open
Abstract
Patients with head and neck cancer report high unmet psychosocial needs as they undergo lifesaving treatments that can significantly alter their appearance and cause functional impairments. This qualitative analysis of recordings of 88 pre- and post-surgical consultations involving 20 patients respond to the need for empirical studies of patient–provider conversations about body image concerns. It indicates that the emphasis on concerns about survival, cure, and physical recovery during clinical consultations may leave concerns about the impacts of surgery on appearance and function unexplored and even silenced. The interviews with patients and medical team members that complement the analysis of the recordings suggest that an emphasis on survival, cure, and physical recovery can respond to the need for reassurance in the context of serious illness. However, it can also be problematic as it contributes to the silencing of patients’ concerns and to a potential lack of preparedness for the consequences of surgery. The results of this study can contribute to raising surgeons’ awareness of the interactional dynamics during clinical consultations. Moreover, the results highlight the unique role that surgeons can play in validating patients’ psychosocial concerns to support patients’ rehabilitation in both physical and psychosocial domains.
Collapse
Affiliation(s)
- Maria Cherba
- Department of Communication, University of Ottawa, Ottawa, ON K1N 6N5, Canada
- Correspondence:
| | | | - Michael P. Hier
- Department of Otolaryngology—Head and Neck Surgery, McGill University, Montreal, QC H3A 0G4, Canada; (M.P.H.); (V.-I.F.); (A.M.)
- Department of Otolaryngology—Head and Neck Surgery, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Lauriane Giguère
- School of Psychology, University of Ottawa, Ottawa, ON K1N 6N5, Canada;
| | - Gabrielle Chartier
- Department of Nursing, Oncology Division, Jewish General Hospital, Montreal, QC H3T 1E2, Canada;
| | - Hannah Jacobs
- Department of Audiology and Speech-Language Pathology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada;
| | - Véronique-Isabelle Forest
- Department of Otolaryngology—Head and Neck Surgery, McGill University, Montreal, QC H3A 0G4, Canada; (M.P.H.); (V.-I.F.); (A.M.)
- Department of Otolaryngology—Head and Neck Surgery, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Alex Mlynarek
- Department of Otolaryngology—Head and Neck Surgery, McGill University, Montreal, QC H3A 0G4, Canada; (M.P.H.); (V.-I.F.); (A.M.)
- Department of Otolaryngology—Head and Neck Surgery, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| | - Khalil Sultanem
- Division of Radiation Oncology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada;
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada;
| | - Melissa Henry
- Gerald Bronfman Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada;
- Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
- Segal Cancer Centre, Jewish General Hospital, Montreal, QC H3T 1E2, Canada
| |
Collapse
|
3
|
Erasmus R, Fourie P, Janse van Rensburg C, Jacobs H. An audit on the accuracy of freehand acetabular cup positioning in total hip arthroplasty with the direct lateral approach at a tertiary institution over seven years. SA orthop j 2022. [DOI: 10.17159/2309-8309/2022/v21n4a2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND: The direct lateral approach for total hip replacement has been traditionally reserved and described for neck of femur fractures. Advantages of this approach include technically easy access to the acetabulum and femur and low incidence of hip dislocation. Imperfect positioning of the acetabular component leads to increased risk for dislocations, accelerated wear, reduced range of motion and increased revision rate. Freehand technique has been the gold standard for many decades, but newer technologies like computer navigation and robotic-assisted surgery have shown to improve the accuracy of cup placement. This study reports on the accuracy of freehand cup positioning via the direct lateral approach with mention of the dislocation rate METHODS: We retrospectively reviewed 253 patients who had total hip replacements done via the direct lateral approach. The patients' files were evaluated for patient parameters, demographic details, aetiology of hip pathology, confirmation of approach used, comorbidities and history of previous relevant surgery. The postoperative radiographs were analysed for acetabular component position inclination and anteversion. Dislocation rates were calculated as a secondary objective RESULTS: The radiographic analysis was performed using the Liaw method based on trigonometry of the eclipse generated. This showed a mean cup inclination of 42.3° (95% CI: 41.3-43.3°) and anteversion of 12.7° (95% CI: 12.0-13.7°). A total of 57% of the acetabular cups were within the safe zones described by Lewinnek. Of them, 78% were in the 30-50° range for inclination and 73% in the 5-25° range for anteversion. There were ten dislocations within one year from the index procedure: a dislocation rate of 4.0% (95% CI: 2.8-8.5% CONCLUSION: The freehand technique using the direct lateral approach for acetabular cup placement produces a poor overall accuracy of only 57%. Although our study only commented on ten dislocations, the rate (4%) is significantly worse compared to the 0.43% reported in literature for the direct lateral approach. The radiographic results for inclination and anteversion are comparable to other freehand techniques, regardless of the approach used, but significantly worse than results achieved with navigation and robotics Level of evidence: Level 4
Collapse
|
4
|
Willemsen L, Neele A, Prange K, Roomen C, Bruinenberg DAL, Den Toom M, Griffith G, Chen HJ, Beckers L, Bosmans L, Binder C, Van Leeuwen F, Jacobs H, De Winther M. Histone methyltransferase DOT1L regulates macrophage inflammatory responses and lipid metabolism. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
5
|
Joshi H, Lin S, Fei K, Renteria AS, Jacobs H, Mazumdar M, Jagannath S, Bickell NA. Multiple myeloma, race, insurance and treatment. Cancer Epidemiol 2021; 73:101974. [PMID: 34243048 DOI: 10.1016/j.canep.2021.101974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 05/10/2021] [Accepted: 06/19/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE Multiple Myeloma (MM), the second leading blood malignancy, has complex and costly disease management. We studied patterns of treatment disparities and unplanned interruptions among the MM patients after the Affordable Care Act to assess their prevalence and effect on survival. MATERIALS AND METHODS This retrospective study of 1002 MM patients at a tertiary referral center used standard guidelines as a reference to identify underuse of effective treatments. We used multivariate logistic regression and Cox proportionate hazard to study the prognostic effect on survival. RESULTS Median age in the cohort was 63.0 [IQR: 14] years. Non-Hispanic White (NHW) patients were older (p = 0.007) and more likely to present with stage I disease (p = 0.02). Underuse of maintenance therapy (aOR = 1.98; 95 % CI 1.12-3.48) and interruptions in treatment were associated with race/ethnicity and insurance (aOR = 4.14; 95 % CI: 1.78-9.74). Only underuse of induction therapy was associated with overall patient survival. CONCLUSION Age, race, ethnicity and primary insurance contribute to the underuse of treatment and in unplanned interruptions in MM treatment. Addressing underuse causes in such patients is warranted.
Collapse
Affiliation(s)
- Himanshu Joshi
- Institute for Healthcare Delivery Science, NY, NY, United States; Department of Population Health Science and Policy, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Sylvia Lin
- Department of Population Health Science and Policy, NY, NY, United States
| | - Kezhen Fei
- Department of Population Health Science and Policy, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Anne S Renteria
- Department of Hematology and Medical Oncology, NY, NY, United States
| | - Hannah Jacobs
- Department of Population Health Science and Policy, NY, NY, United States
| | - Madhu Mazumdar
- Institute for Healthcare Delivery Science, NY, NY, United States; Department of Population Health Science and Policy, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States
| | - Sundar Jagannath
- Department of Hematology and Medical Oncology, NY, NY, United States
| | - Nina A Bickell
- Department of Population Health Science and Policy, NY, NY, United States; Center for Health Equity and Community Engaged Research, NY, NY, United States; Tisch Cancer Institute all at the Icahn School of Medicine at Mount Sinai, NY, NY, United States.
| |
Collapse
|
6
|
Koprda O, Sokolovic L, Dronse J, Jacobs H, Dillen K, Richter N, Reutern BV, Langen K, Onur I, Fink G, Kukolja J. P87 The effect of periventricular white matter hyperintensities on functional connectivity and cognitive performance in elderly adults. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Watt FE, Blauwet MB, Fakhoury A, Jacobs H, Smulders R, Lane NE. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. Osteoarthritis Cartilage 2019; 27:1590-1598. [PMID: 31356878 DOI: 10.1016/j.joca.2019.05.029] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2019] [Revised: 05/05/2019] [Accepted: 05/29/2019] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To investigate the TrkA inhibitor, ASP7962, for treatment of painful knee osteoarthritis. DESIGN Phase 2a, double-blind, placebo- and naproxen-controlled, double-dummy, parallel-group study. Adults with knee osteoarthritis were randomized (2:2:1) to ASP7962 (100 mg), placebo, or naproxen (500 mg) twice daily (BID) for 4 weeks. Primary endpoint: change from baseline to Week 4 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale score. Secondary endpoints: change from baseline to Weeks 1, 2, and End of Treatment (EoT) in WOMAC pain subscale score; change from baseline to Weeks 1, 2, 4, and EoT in WOMAC physical function and stiffness subscales, walking pain and WOMAC total scores; and change from baseline in daily average pain score. RESULTS 215 participants were randomized (ASP7962 100 mg BID, n = 85; placebo, n = 87; naproxen 500 mg BID, n = 43). No significant difference was observed between ASP7962 and placebo in change from baseline to Week 4 in WOMAC pain subscale score (-0.14; 90% 2-sided CI: -0.62, 0.34; P = 0.316); a significant difference was observed between naproxen and placebo (-0.67; 80% 2-sided CI: -1.12, -0.23; P = 0.027). No differences were observed between ASP7962 and placebo in change from baseline in any WOMAC subscale score; statistically significant changes were observed between naproxen and placebo (P ≤ 0.01, all time points for all WOMAC endpoints). ASP7962 was safe and well-tolerated. CONCLUSIONS Four-week treatment with ASP7962 (100 mg BID) did not improve pain or physical function in individuals with painful knee osteoarthritis. ClinicalTrials.gov, NCT02611466; EudraCT Number, 2014-004996-22.
Collapse
Affiliation(s)
- F E Watt
- Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive Headington, Oxford, UK.
| | - M B Blauwet
- Astellas Pharma Global Development, Northbrook, IL, USA.
| | - A Fakhoury
- Astellas Pharma Global Development, Northbrook, IL, USA.
| | - H Jacobs
- Formerly with Astellas Pharma Global Development, Leiden, the Netherlands.
| | - R Smulders
- Astellas Pharma Global Development, Northbrook, IL, USA.
| | - N E Lane
- Center for Musculoskeletal Health, University of California at Davis Medical Center, Sacramento, CA, USA.
| |
Collapse
|
8
|
Pilzecker B, Buoninfante O, Song J, Pritchard C, Huijbers I, Vivié J, Philipsen S, Van den Berk P, Jacobs H. PO-397 DNA damage tolerance is essential for the DNA damage response network and hematopoietic stem cell maintenance. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
9
|
Jacobs H, Hogenbirk M. SPOT-001 Molecular and biophysical determinants of chromosomal translocations: a multiomics approach. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
10
|
Abstract
This paper describes a system for dealing with a certain kind of textual information. The system has been in operation for about one and a half years. It also indicates the nature of a new and greatly expanded system presently under development.The first system consists essentially of three parts, of which the most important is a thesaurus processor. The assumption is made that document content depends only on word content and that word relationships are defined by an hierarchical structure. The function of the thesaurus processor is to provide a simple language for developing and changing the thesaurus, whenever change is necessary. The remaining parts of the first system are a document processor for updating document files, and a search processor for batch requests which must scan the entire document file. Some statistics are given on performance of the system.The second system includes a thesaurus processor of expanded capability. It also includes a newly developed search language, which can be used to scan records for complex patterns of events. Input-output processing of records and of search results is left to the user of the system.
Collapse
|
11
|
Müller-Ehrenberg L, Verhey F, Sack A, Jacobs H. P203 Is more better? A protocol to investigate the (neural) effects of repeated vs. single tACS in healthy and pathological ageing. Clin Neurophysiol 2017. [DOI: 10.1016/j.clinph.2016.10.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Jacobs H, Van de Werf F, Lesaffre E, De Geest H, Collen D. A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters. Acta Clin Belg 2016; 47:82-9. [PMID: 1352930 DOI: 10.1080/17843286.1992.11718214] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Coronary artery disease is frequently associated with disturbed blood lipids and with a deficient blood fibrinolytic capacity. In order to investigate a possible link between hypercholesterolemia and hypofibrinolysis, we have investigated the effect of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters in a double blind, randomized, placebo controlled study design. Twenty-four male patients, aged between 42 and 65 years, with angiographically confirmed coronary artery disease, were selected from a series of 731 consecutive patients on the basis of a fasting serum cholesterol level of more than 250 mg/dl and a plasma PAI-1 level of more than 60 ng/ml. Patients were randomly assigned to 20 mg of simvastatin daily (Group I), or placebo (Group II), for four weeks, followed by doubling of the dose for another four weeks. Blood samples were obtained at baseline and at 4 and 8 weeks. Groups I and II did not differ significantly at baseline. As expected, simvastatin produced a significant reduction in serum levels of total cholesterol (33 +/- 12 and 36 +/- 12 percent, mean +/- SD, after 4 and 8 weeks respectively, p less than 0.001 vs baseline), LDL-cholesterol (36 +/- 5 and 43 +/- 6 percent respectively, p less than 0.001 vs baseline) and apolipoprotein-B (20 +/- 29 and 23 +/- 30 percent respectively, p less than 0.05 vs baseline), whereas these parameters did not change significantly in the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- H Jacobs
- Division of Cardiology, University of Leuven, Belgium
| | | | | | | | | |
Collapse
|
13
|
|
14
|
van der Ven M, Ten Cate D, Gerards A, Jacobs H, Swen N, de Jager M, Basoski N, Haagsma C, Hazes M, Luime J. SAT0586 Ultrasonographic Signs Of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients who are Treated to Target. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
15
|
Jacobs H, Grieshaber M, Schneider U, Henrich P, Goldblum D. Torische Intraokularlinsen: Eine nützliche Methode in der Korrektur des kornealen Astigmatismus. Klin Monbl Augenheilkd 2015; 232:372-4. [DOI: 10.1055/s-0035-1545815] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- H. Jacobs
- Augenklinik, Universitätsspital Basel, Schweiz
| | | | | | - P. Henrich
- Augenklinik, Universitätsspital Basel, Schweiz
| | - D. Goldblum
- Augenklinik, Universitätsspital Basel, Schweiz
| |
Collapse
|
16
|
Affiliation(s)
- W. Bockelmann
- Institut für Anorganische Chemie der Universität Kiel
| | - H. Jacobs
- Institut für Anorganische Chemie der Universität Kiel
| | | |
Collapse
|
17
|
Stuhr A, Jacobs H, Juza R. Notizen: Die Kristallstruktur des Na3[Y(NH2)6] / The crystal structure of Na3[Y(NH2)6]. Zeitschrift für Naturforschung B 2014. [DOI: 10.1515/znb-1970-1238] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- A. Stuhr
- Institut für Anorganische Chemie der Universität Kiel
| | - H. Jacobs
- Institut für Anorganische Chemie der Universität Kiel
| | - R. Juza
- Institut für Anorganische Chemie der Universität Kiel
| |
Collapse
|
18
|
Stuhr A, Jacobs H. Notizen: Die Krisallstruktur des Na[Yb(NH2)4] / The crystal structure of Na[Yb (NH2) 4]. Zeitschrift für Naturforschung B 2014. [DOI: 10.1515/znb-1971-0224] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- A. Stuhr
- Institut für anorganische Chemie der Universität Kiel
| | - H. Jacobs
- Institut für anorganische Chemie der Universität Kiel
| |
Collapse
|
19
|
Lutz HD, Henning J, Jacobs H, Harbrecht B. Hydrogen Bonding and Phase Transitions of RbOH · H2O and CsOH · H2O Studied by IR and Raman Spectroscopy. ACTA ACUST UNITED AC 2014. [DOI: 10.1002/bbpc.198800368] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
20
|
Lamers-Karnebeek FBG, Jacobs H, Fransen J, Luime J, Riel P, Jansen T. THU0152 The Poet-Us Study: Can Ultrasonography Predict Flare in Patients with RA and Persistent Low Disease Activity in Whom the Tnfinhibitor (TNFI) is Stopped? Preliminary Results of an Ongoing Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.680] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Sieuwerts AM, Burns M, Look MP, Meijer-Van Gelder ME, Schlicker A, Heidemann MR, Jacobs H, Wessels L, Willis S, Leyland-Jones B, Gray K, Foekens JA, Harris RS, Martens JW. Abstract S6-05: High levels of APOBEC3B, a DNA deaminase and an enzymatic source of C-to-T transitions, are a validated marker of poor outcome in estrogen receptor-positive breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-s6-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Two recent observations have connected the innate immune DNA cytosine deaminase APOBEC3B to the genetic evolution of breast cancer. First, APOBEC3B was shown to be up-regulated in the majority of breast cancers, and, in breast cancer cell lines, its activity was causally linked to a doubling of the number of C-to-T transitions over time and to a delay in cell cycle progression (1). Second, sequencing of the complete genome of 21 breast cancers independently suggested that APOBEC deaminase activity could be responsible for 2 of 5 mutational imprints identified, which involved clustered (also called kataegis) and dispersed C-to-T transition mutations in the context of 5’TC dinucleotide motifs (2).
In the current study, we addressed a possible association of APOBEC3B expression with outcome in clinical breast cancer. For this we measured using real-time RT-PCR APOBEC3B mRNA levels in 1,491 primary invasive breast cancers and correlated these levels with disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) using univariate and multivariable Cox regression analysis. In addition, we independently validated our findings in available gene expression datasets with appropriate follow-up.
In univariate analyses including all patients, increasing levels of APOBEC3B mRNA analyzed as a continuous variable were significantly associated with shorter DFS, MFS and OS (Hazard Ratio [HR] = 1.29, 1.31 and 1.36, respectively, all P<0.001). To determine the relation of APOBEC3B mRNA expression with the natural course of the disease without the potential confounding effects of systemic adjuvant therapy, we restricted our next analyses to MFS in 829 patients with lymph node-negative disease who had not received any (neo)adjuvant systemic therapy. This analysis showed that APOBEC3B mRNA expression was, in univariate, and in multivariable analysis, including the traditional prognostic factors (age, menopausal status, tumor size, grade and steroid hormone receptors), a marker of pure prognosis specifically in patients with estrogen receptor-positive (ER+) disease (univariate HR = 1.30; P = 0.003; multivariate HR = 1.22, P = 0.042).
To substantiate and validate our findings, we analysed 4 independent available datasets containing in total 5,760 breast cancer cases in which APOBEC3B mRNA expression was measured by probes on microarrays and found that higher APOBEC3B mRNA expression (dichotomised by mean) was significantly associated with poor outcome in all 4 cohorts ([Metabric, 1,491 ER+ cases, HR = 1.82; P<0.001], [Affymetrix compiled dataset-1, 2,407 cases, HR = 2.22; P = 0.001], and [BIG 1-98; 1,207 cases, HR = 2.13; P<0.001 of late recurrence>5 years], and [Affymetrix dataset-2, 643 ER+ cases, HR = 2.04; P = 0.001]).
Altogether, our analyses show that APOBEC3B mRNA - and as a result likely DNA deamination – is a validated predictor of poor outcome in breast cancer, supporting the notion that APOBEC3B is a potentially interesting clinical target for therapeutic intervention to prevent breast cancer progression and metastasis, particularly in ER+ disease.
1. Burns, M.B. et al. Nature 494, 366-70 (2013); 2. Nik-Zainal, S. et al. Cell 149, 979-93 (2012).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr S6-05.
Collapse
Affiliation(s)
- AM Sieuwerts
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - M Burns
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - MP Look
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - ME Meijer-Van Gelder
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - A Schlicker
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - MR Heidemann
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - H Jacobs
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - L Wessels
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - S Willis
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - B Leyland-Jones
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - K Gray
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - JA Foekens
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - RS Harris
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| | - JW Martens
- Erasmus MC Cancer Institute, Cancer Genomics Netherlands, Erasmus University Medical Centre, Rotterdam, Netherlands; University of Minnesota, Minneapolis, MN; The Netherlands Cancer Institute, Amsterdam, Netherlands; Sanford Health and Research, Sioux Falls, SD; Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
22
|
Lewis-Holmes E, Taylor E, Pitfield C, Morris J, Wills G, Carson N, Jacobs H, Livingston G. Supportive, interactive staff training may improve outcomes for residents dying in a care home. BMJ Support Palliat Care 2012. [DOI: 10.1136/bmjspcare-2012-000264.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
23
|
Livingston G, Pitfield C, Morris J, Manela M, Lewis-Holmes E, Jacobs H. Care at the end of life for people with dementia living in a care home: a qualitative study of staff experience and attitudes. Int J Geriatr Psychiatry 2012; 27:643-50. [PMID: 21858871 DOI: 10.1002/gps.2772] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2011] [Accepted: 07/04/2011] [Indexed: 11/08/2022]
Abstract
OBJECTIVE The aim of this study is to examine barriers and facilitators to care home staff delivering improved end-of-life care for people with dementia. METHOD Individual qualitative interviews of 58 staff in a 120-bed nursing home where the staff and the residents' religion differed were carried out. Interviews continued until a maximum variation sample was achieved and theoretical saturation was reached. RESULTS The staff felt warmly towards the residents and felt they could recognise when they were near death. Care staff, nurses and doctors did not see themselves as a team and communicated poorly with relatives about approaching death. The staff used opaque euphemisms and worried about being blamed. They were often unaware of or had concerns about the validity of advance care plans. They knew of the religious rituals around death but frequently misunderstood religious tradition. CONCLUSION The staff require education and support about discussing and implementing plans around care at the end of life in dementia and about cultural issues around death to improve practice. This would enable the staff to implement advance care plans, knowing that they will be supported. Education would encompass communicating the complicated, unpredictable path of dementia near the time of death explicitly but sensitively, including recognising that people often do not hear difficult messages and are unable to take on large quantities of information at once. The staff need to know about the resident's religious and cultural ideas as well as ritual practice.
Collapse
|
24
|
Badal S, Williams S, Huang G, Francis S, Vedantam P, Dunbar O, Jacobs H, Tzeng T, Gangemi J, Delgoda R. Erratum to “Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri” [Fitoterapia 82 (2011) 230–236]. Fitoterapia 2011. [DOI: 10.1016/j.fitote.2011.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
25
|
Jacobs H, Koek GH, Peters R, Moalin M, Tack J, van der Vijgh WJ, Bast A, Haenen GR. Differences in Pharmacological Activities of the Antioxidant Flavonoid MonoHER in Humans and Mice Are Caused by Variations in Its Metabolic Profile. Clin Pharmacol Ther 2011; 90:852-9. [DOI: 10.1038/clpt.2011.200] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
|
26
|
Boumans MJH, Houbiers JGA, Verschueren P, Ishikura H, Westhovens R, Brouwer E, Rojkovich B, Kelly S, den Adel M, Isaacs J, Jacobs H, Gomez-Reino J, Holtkamp GM, Hastings A, Gerlag DM, Tak PP. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study. Ann Rheum Dis 2011; 71:180-5. [PMID: 21917822 DOI: 10.1136/annrheumdis-2011-200298] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES Osteopontin is an extracellular matrix protein with diverse immunomodulatory functions. The authors assessed the safety, tolerability, pharmacokinetics, pharmacodynamics and initial efficacy of the humanised monoclonal antibody ASK8007, which blocks osteopontin. METHODS In this double-blind, multicentre, combined first-in-man, single-dose escalation (phase I, part A) and proof-of-concept, multiple-dose (phase IIA, part B) study, rheumatoid arthritis (RA) patients with active disease were randomly assigned to receive ASK8007 or placebo intravenously. Safety monitoring, pharmacokinetic and pharmacodynamic analyses and clinical assessments were performed throughout the study. The expression of phenotypic cell markers was evaluated in synovial tissue biopsy samples obtained at baseline and 43 days after initiation of treatment (part B) by immunohistochemistry and digital image analysis. Two co-primary efficacy endpoints were the change from baseline in the disease activity score evaluated in 28 joints (DAS28) and the change from baseline in the number of CD68 synovial sublining macrophages, both assessed on day 43 (part B). RESULTS ASK8007 was overall safe and well tolerated up to the highest studied dose (20 mg/kg). Quantifiable concentrations of ASK8007 were detected in synovial fluid. No differences were observed for changes from baseline in DAS28 and CD68 sublining macrophages between ASK8007 and placebo-treated patients. Within the ASK8007 treatment group, there were also no apparent clinical responses or changes in sublining macrophages. In addition, ASK8007 treatment did not change other assessed biomarkers. CONCLUSIONS Osteopontin blockade is well tolerated and not related to safety concerns. These results consistently show that osteopontin blockade is unlikely to induce robust clinical improvement in RA patients.
Collapse
Affiliation(s)
- M J H Boumans
- Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Thum A, Haag A, Rösler J, Jacobs H, Hermsen A, Huber M, Knake S, Rosenow F, Oertel WH, Hamer HM. Verbal declarative memory and language lateralization in patients with major depression: A functional transcranial Doppler sonography (fTCD) study. Pharmacopsychiatry 2011. [DOI: 10.1055/s-0031-1292552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
28
|
Badal S, Williams S, Huang G, Francis S, Vendantam P, Dunbar O, Jacobs H, Tzeng T, Gangemi J, Delgoda R. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011; 82:230-6. [DOI: 10.1016/j.fitote.2010.10.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2010] [Revised: 09/27/2010] [Accepted: 10/05/2010] [Indexed: 11/30/2022]
|
29
|
Jacobs H, Bast A, Peters GJ, van der Vijgh WJF, Haenen GRMM. The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB. Br J Cancer 2011; 104:437-40. [PMID: 21245867 PMCID: PMC3049564 DOI: 10.1038/sj.bjc.6606065] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Background: Despite therapeutic advances, the prognosis of patients with metastatic soft tissue sarcoma (STS) remains extremely poor. The results of a recent clinical phase II study, evaluating the protective effects of the semisynthetic flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) on doxorubicin-induced cardiotoxicity, suggest that monoHER enhances the antitumour activity of doxorubicin in STSs. Methods: To molecularly explain this unexpected finding, we investigated the effect of monoHER on the cytotoxicity of doxorubicin, and the potential involvement of glutathione (GSH) depletion and nuclear factor-κB (NF-κB) inactivation in the chemosensitising effect of monoHER. Results: MonoHER potentiated the antitumour activity of doxorubicin in the human liposarcoma cell line WLS-160. Moreover, the combination of monoHER with doxorubicin induced more apoptosis in WLS-160 cells compared with doxorubicin alone. MonoHER did not reduce intracellular GSH levels. On the other hand, monoHER pretreatment significantly reduced doxorubicin-induced NF-κB activation. Conclusion: These results suggest that reduction of doxorubicin-induced NF-κB activation by monoHER, which sensitises cancer cells to apoptosis, is involved in the chemosensitising effect of monoHER in human liposarcoma cells.
Collapse
Affiliation(s)
- H Jacobs
- Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Sciences, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre+, P.O. Box 616, 6200 MD, Maastricht, The Netherlands.
| | | | | | | | | |
Collapse
|
30
|
Meuris B, Van Meirhaeghe S, Jacobs H, Flameng W. Giant aortic aneurysm after 35 years' uneventful survival, without anticoagulation, with a Björk-Shiley aortic valve. J Heart Valve Dis 2010; 19:809-810. [PMID: 21214115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
|
31
|
Hermsen A, Jacobs H, Rösler J, Haag A, Huber M, Thum A, Knake S, Rosenow F, Oertel W, Hamer H. Sprachdominanz und Verbalgedächtnis bei Patienten mit Schizophrenie – eine Studie mittels funktioneller transkranieller Dopplersonographie. Akt Neurol 2008. [DOI: 10.1055/s-0028-1086958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Haag A, Rösler J, Jacobs H, Hermsen A, Huber M, Thum A, Knake S, Rosenow F, Oertel W, Hamer H. Untersuchung der Sprachdominanz mittels funktioneller transkranieller Dopplersonographie (fTCD) bei Patienten mit rezidivierender depressiver Störung – Zusammenhang zum Verbalgedächtnis. Akt Neurol 2008. [DOI: 10.1055/s-0028-1086947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
33
|
van de Wiele T, Boon N, Possemiers S, Jacobs H, Verstraete W. Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. J Appl Microbiol 2007; 102:452-60. [PMID: 17241351 DOI: 10.1111/j.1365-2672.2006.03084.x] [Citation(s) in RCA: 172] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
AIMS We assessed to what extent fructans of different degrees of polymerization (DP) differ in their prebiotic effectiveness towards in vitro microbial communities from the proximal and distal colon. METHODS AND RESULTS Two short chain fructans - oligofructose (DP 2-20) and inulin (DP 3-60) - were administered to the Simulator of the Human Intestinal Microbial Ecosystem (SHIME) at 2.5 g day(-1). The influence of fructan addition towards fermentation activity and microbial community composition from the different SHIME colon compartments were evaluated. Both fructans exerted prebiotic effects with significantly higher butyrate and propionate production and stimulation of lactic acid-producing bacteria. Compared with oligofructose, it was noted that it took more time before significant effects from inulin addition were observed. Yet, the higher short-chain fatty acid production and lower proteolytic activity showed that the prebiotic effects from inulin were more pronounced than oligofructose. Also, the bifidogenic effects from inulin vs oligofructose were higher in the distal colon compartments and this effect was prolonged in the distal colon once the addition was stopped. CONCLUSIONS Inulin has more pronounced prebiotic effects than oligofructose towards both fermentation activity and bacterial community composition in the SHIME model. SIGNIFICANCE AND IMPACT OF THE STUDY Its slower fermentation rate and higher prebiotic potency makes inulin a more interesting compound than oligofructose to beneficially influence the microbial community from both the proximal and distal colon regions.
Collapse
Affiliation(s)
- T van de Wiele
- Laboratory Microbial Ecology and Technology (LabMET), Ghent University, Ghent, Belgium.
| | | | | | | | | |
Collapse
|
34
|
Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs H, van der Graaf Y, Visseren F. We-P13:338 Serum uric acid levels and risk for cardiovascular diseases in patients with and without the metabolic syndrome. ATHEROSCLEROSIS SUPP 2006. [DOI: 10.1016/s1567-5688(06)81691-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Kasten M, Hagenah J, Hauenschild S, Jacobs H, Kabakci K, Pramstaller P, Vieregge P, Klein C. Fünf-Jahres-Nachuntersuchung von Parkinsonpatienten mit und ohne Parkin-Mutationen. Akt Neurol 2005. [DOI: 10.1055/s-2005-919516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Seeram N, Francis L, Needham O, Jacobs H, McLean S, Reynolds W. Drimane and bisabolane sesquiterpenoids from Cinnamodendron corticosum (Canellaceae). BIOCHEM SYST ECOL 2003. [DOI: 10.1016/s0305-1978(02)00203-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
|
38
|
Haarmann F, Jacobs H, Kockelmann W, Senker J, Müller P, Kennedy CA, Marriott RA, Qiu L, White MA. Dynamics of anions and cations in cesium hydrogensulfide (CsHS, CsDS): Neutron and x-ray diffraction, calorimetry and proton NMR investigations. J Chem Phys 2002. [DOI: 10.1063/1.1479141] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Perrin S, Fougnies C, Grill JP, Jacobs H, Schneider F. Fermentation of chicory fructo-oligosaccharides in mixtures of different degrees of polymerization by three strains of bifidobacteria. Can J Microbiol 2002; 48:759-63. [PMID: 12381033 DOI: 10.1139/w02-065] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We estimated and compared the action of three selected strains of bifidobacteria in a semi-synthetic medium for different degrees of polymerization of fructo-oligosaccharides contained in three commercial products derived from chicory inulin: Fibrulose F97 (shorter chains), Fibruline Instant (native chains), Fibruline LC (longer chains). Biomass and production of lactate and acetate were greater when the substrate contained mostly shorter chain fructo-oligosaccharides. Shorter chains were first to be consumed, and one strain could use longer chains. As the degree of polymerization increased, residual fructo-oligosaccharides increased after growth of the strains, and the rate of consumption of fructo-oligosaccharides decreased.
Collapse
Affiliation(s)
- S Perrin
- Laboratoire de Biochimie des Bactéries Gram+, Université Henri Poincaré-Nancy I, Faculté des Sciences et Techniques, Vandoeuvre-lès-Nancy, France
| | | | | | | | | |
Collapse
|
40
|
Haarmann F, Jacobs H, Senker J, Rössler E. Dynamics of anions and cations in hydrogensulfides of alkali metals (NaHS, KHS, RbHS): A proton nuclear magnetic resonance study. J Chem Phys 2002. [DOI: 10.1063/1.1483860] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Kann M, Hedrich K, Vieregge P, Jacobs H, Müller B, Kock N, Schwinger E, Klein C, Marder K, Harris J, Meija-Santana H, Bressman S, Ozelius LJ, Lang AE, Pramstaller PP. The parkin gene is not involved in late-onset Parkinson's disease. Neurology 2002; 58:835; author reply 835. [PMID: 11889262 DOI: 10.1212/wnl.58.5.835] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Harding WW, Jacobs H, Lewis PA, McLean S, Reynolds WF. Cycloartanes, protolimonoids, a pregnane and a new ergostane from Trichilia reticulata. Nat Prod Lett 2002; 15:253-60. [PMID: 11833620 DOI: 10.1080/10575630108041289] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The new ergostane steroid ergosta-5,24(24')-diene-3beta,4beta,22R-triol (1), a pregnane, (E)-volkendusin, characterised as the diacetate (3), cycloartanes 4-6 and protolimonoids 7-9 were obtained from the leaves and twigs of Trichilia reticulata.
Collapse
Affiliation(s)
- W W Harding
- Chemistry Department, University of the West Indies, Mona, Jamaica
| | | | | | | | | |
Collapse
|
43
|
Abstract
The metallic interstitial nitride Ni(3)N was prepared from Ni(NH(3))(6)Cl(2) and NaNH(2) in supercritical ammonia (p(NH(3)) approximately 2 kbar) at 523 K. Its previously reported crystal structure, as determined from X-ray powder data, was confirmed by neutron powder diffraction: Ni(3)N crystallizes in the hexagonal epsilon-Fe(3)N-type structure (P6(3)22, Z = 2, a = 4.6224 A and c = 4.3059 A at room temperature). The N atoms on the octahedral sites of an hcp arrangement of Ni show virtually complete occupational order at ambient temperatures, which is preserved up to its thermal decomposition at T approximately 600 K. This behavior is in marked contrast to that of the isotypic iron nitride, epsilon-Fe(3)N, which shows reversible partial disordering within the same range of temperatures. Possible reasons for the different behaviors of the two nitrides epsilon-Fe(3)N and Ni(3)N are discussed.
Collapse
Affiliation(s)
- A Leineweber
- Lehrstuhl Anorganische Chemie, Fachbereich Chemie der Universität, 44221 Dortmund, Germany
| | | | | |
Collapse
|
44
|
Abstract
Monoclonal antibodies against glutamic acid decarboxylase (anti-GAD) were modified with poly(ethylene glycol) (PEG), and the resulting conjugates were characterized. Monoclonal anti-GAD antibodies were purified from ATCC HB184 hybridoma cells by either cell culture supernatant or ascites fluid from BALB/c mice. Polyclonal rabbit IgG antibodies were also used as a model protein. Polyclonal rabbit IgG or purified anti-GAD was modified by PEG (MW = 5000 or 20000 Da) through either the lysine residues or through the carbohydrate moiety. Lysine modification was performed in PBS (pH 7.4) or 0.1 M borate (pH 9.2) by adding a molar excess (5-80) of a succinimidyl activated propionic acid terminated mPEG (SPA-PEG) while stirring at room temperature. Carbohydrate modifications were performed in PBS (pH 6.2) by first oxidizing the antibody with sodium periodate followed by incubation with hydrazide-terminated PEG followed by reduction with sodium cyanoborohydride. The degree of modification was assessed by 1H NMR or TNBS (trinitrobenzenesulfonic acid). Circular dichroism (CD) spectra were obtained for lysine-modified rabbit IgG at various degrees of modification ranging from 5 to 60 PEG per antibody. Binding was assessed using an ELISA method with GAD or rabbit anti-mouse-IgG (H+L) coated plates. The TNBS and 1H NMR analysis of the modified antibody showed reasonably similar results from 5 to 60 PEG per antibody. The 1H NMR method showed greater sensitivity at low modifications (below 20:1) and was fairly linear up to about 60 PEG per antibody. The CD spectra of the polyclonal rabbit IgG showed only small differences at variously modified antibody. The binding affinity of anti-GAD is lower for all PEG modifications with respect to unmodified anti-GAD. Modifications at pH 7.4 show lower binding to GAD than modifications at pH 9.2. Binding to GAD or anti-mouse-IgG is decreased as the degree of modification is increased. Lysine modifications showed lower binding to GAD or anti-mouse-IgG than carbohydrate modifications. Binding to GAD or anti-mouse-IgG is lower for PEG20000-modified anti-GAD with respect to PEG5000-modified anti-GAD.
Collapse
Affiliation(s)
- R S Larson
- Center for Controlled Chemical Delivery, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 30 South 2000 East Room 201, Salt Lake City, Utah 84112, USA
| | | | | | | |
Collapse
|
45
|
Jacobs H. I took a walk this afternoon. Posit Living 2001; 10:5, 31. [PMID: 11702761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
|
46
|
Abstract
BACKGROUND An inverse association between cigarette smoking and the risk of idiopathic PD has been found in many epidemiologic studies. The therapeutic and possible neuroprotective effects of nicotine formulations on parkinsonian symptoms are controversial. METHODS In a 12-week, randomized, double-blind, placebo-controlled trial, the efficacy and tolerability of transdermal nicotine patches as an add-on treatment for cardinal symptoms were evaluated in 32 nonsmoking patients with PD. After a 1-week run-in phase, patients were randomized to receive nicotine patches (containing 17.5 mg nicotine in the first and 35.0 mg nicotine in the second and third weeks) or identically appearing placebo patches. After this treatment, 3 weeks without patch application followed. The same blinded examiner assessed the patients with the Columbia University Rating Scale, the Webster scale, the Schwab-England scale, a timed walking test, with an instrumental test for fine motor skills and hand tremor, and with the Hamilton Depression Scale. RESULTS No significant drug effects between both groups were observed in any of the scores and quantitative tests. Side effects were mild and comparable in frequency between both groups. CONCLUSIONS With the dosage and the period of treatment chosen, transdermal nicotine patches are not effective as an add-on treatment for symptoms of PD.
Collapse
Affiliation(s)
- A Vieregge
- Department of Neurology, University Hospital of Lübeck, Germany
| | | | | | | | | |
Collapse
|
47
|
Leineweber A, Jacobs H, Eßmann R, Allenspach P, Fauth F, Fischer P. Co(NH3)2Cl2 and Co(ND3)2Cl2: Order-Disorder Behaviour of N(H, D)3 and Antiferromagnetic Structure. Z Anorg Allg Chem 2001. [DOI: 10.1002/1521-3749(200109)627:9<2063::aid-zaac2063>3.0.co;2-t] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
48
|
Jacobs H, Latza U, Vieregge A, Vieregge P. Attitudes of young patients with Parkinson's disease towards possible presymptomatic and prenatal genetic testing. Genet Couns 2001; 12:55-67. [PMID: 11332979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
OBJECTIVE To evaluate the opinions and attitudes of young patients with Parkinson's disease (PD) towards possible presymptomatic and prenatal genetic testing for their illness. BACKGROUND With progress in understanding of the genetic component in the etiology of PD, presymptomatic genetic testing may become available in subgroups of patients. METHODS During a survey on sociodemographic and risk factors 111 PD patients (mean age 45 years: mean age at PD onset 36 years) were given a questionnaire with six items about possible presymptomatic and prenatal genetic testing. RESULTS Fifty-seven patients (5196) had knowledge about presymptomatic and prenatal testing. Eighty patients (72%) would take a presymptomatic test, if they had an autosomal dominant form of PD and if the test were available. The most Important reasons given for taking the test were planning of partnership (40%) and family (48%). When being identified as a carrier of a presumed "Parkinson gene", 78 patients (70%) would decide not to have children. Sixty-three patients (57%) would choose to have prenatal testing. Attitudes were largely independent of sociodemographic and disease variables. CONCLUSIONS When addressed as hypothetical persons at genetic risk, young patients with PD support possible presymptomatic genetic testing and, to a lesser extent, prenatal testing. Attitudes and reasons to participate in such hypothetical testing do not grossly differ from those of at-risk persons in established single-gene autosomal dominant disorders of late onset.
Collapse
Affiliation(s)
- H Jacobs
- Department of Neurology, Medical University of Lübeck, Germany
| | | | | | | |
Collapse
|
49
|
Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, Kramer P, Brin MF, Ozelius LJ, Breakefield XO. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 2001; 3:133-43. [PMID: 11523564 DOI: 10.1007/s100480100111] [Citation(s) in RCA: 132] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Dystonia is a movement disorder involving sustained muscle contractions and abnormal posturing with a strong hereditary predisposition and without a distinct neuropathology. In this study the TOR1A (DYT1) gene was screened for mutations in cases of early onset dystonia and early onset parkinsonism (EOP), which frequently presents with dystonic symptoms. In a screen of 40 patients, we identified three variations, none of which occurred in EOP patients. Two infrequent intronic single base pair (bp) changes of unknown consequences were found in a dystonia patient and the mother of an EOP patient. An 18-bp deletion (Phe323_Tyr328del) in the TOR1A gene was found in a patient with early onset dystonia and myoclonic features. This deletion would remove 6 amino acids close to the carboxy terminus, including a putative phosphorylation site of torsinA. This 18-bp deletion is the first additional mutation, beyond the GAG-deletion (Glu302/303del), to be found in the TOR1A gene, and is associated with a distinct type of early onset dystonia.
Collapse
Affiliation(s)
- J C Leung
- Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
This study examined whether a rat model of surgically-induced endometriosis that reduces fertility also evokes vaginal hyperalgesia along with changes in vaginal compliance. In nine rats trained to escape vaginal distention, percent escape responses to different volumes of vaginal distention were measured for 2.5 months before and after endometriosis or sham surgery. Vaginal pressures were also measured simultaneously to provide an estimate of vaginal compliance. Endometriosis (or sham) was induced by autotransplantation of small pieces of uterus (or fat) on mesenteric cascade arteries, abdomen, and ovary. Escape responses were significantly increased only in rats whose autotransplants had formed cysts. Vaginal pressures, however, remained unchanged. This vaginal hyperalgesia may involve a process of viscero-visceral referred hyperalgesia.
Collapse
Affiliation(s)
- K J Berkley
- Program in Neuroscience, Copeland Street, Department of Psychology, Florida State University, Tallahassee, FL 32306-1270, USA.
| | | | | | | | | |
Collapse
|